The company is working to develop a cell therapy platform used for the treatment of solid tumors, according to an April 10 CTRL news release.
“The field of cell therapy has been limited by the lack of tools to isolate and expand tumor-reactive cells that are efficacious against solid tumors,” Shana Kelley, PhD, founder and chief technology officer at CTRL Therapeutics, said in the release. “This funding enables further optimization and validation of our proprietary technology platform and expansion of our team to support our mission to deliver curative therapies for all individuals living with cancer.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
